Your browser doesn't support javascript.
loading
Mortality in patients with unresectable gastric cancer complicated with tumor bleeding.
Amaya-Fragoso, Edgardo; Hernández-Guerrero, Angélica; de la Mora Levy, José Guillermo; Ramírez-Solís, Mauro Eduardo; Alonso-Lárraga, Juan O; Beltrán-Galindo, Luis Guillermo.
Afiliación
  • Amaya-Fragoso E; Gastrointestinal Endoscopy, Instituto Nacional de Cancerología, México.
  • Hernández-Guerrero A; Gastrointestinal Endoscopy, Instituto Nacional de Cancerología.
  • de la Mora Levy JG; Gastrointestinal Endoscopy, Instituto Nacional de Cancerología, México.
  • Ramírez-Solís ME; Gastrointestinal Endoscopy, Instituto Nacional de Cancerología , Mexico .
  • Alonso-Lárraga JO; Gastrointestinal Endoscopy, Instituto Nacional de Cancerología, MEXICO.
  • Beltrán-Galindo LG; Health Sciences, University of York, United Kingdom.
Rev Esp Enferm Dig ; 116(3): 132-139, 2024 Mar.
Article en En | MEDLINE | ID: mdl-37170581
ABSTRACT

BACKGROUND:

gastric cancer (GC) is a gastrointestinal (GI) neoplasia which often complicates with GI bleeding. It is uncertain if bleeding worsens mortality in this group of patients.

AIMS:

to compare 30- and 90-day mortality in patients with unresectable GC (uGC) and tumor bleeding versus patients with the same neoplasia without bleeding.

METHODS:

a retrospective analysis of patients with uGC, with and without tumor bleeding was performed. Survival analysis for 30- and 90-days mortality was performed using Cox regression. Logistic regression was used to identify risk factors associated with mortality and first bleeding episode.

RESULTS:

202 patients were included in the analysis (105 cases). Mortality at 90 days was 37.14 % for cases and 20.62 % for controls (p = 0.04). There was a significant difference in hazard ratio (HR) at 90 days for cases compared to controls (HR 1.95, 95 % CI 1.14-3.34, p = 0.02). Cases without palliative chemotherapy had the highest 90-days mortality (HR 5.43, 95 % CI 2.12-13.87, p < 0.01), compared to controls treated with chemotherapy. Predictors for first tumor bleeding were clinical stage IV (OR 2.93, 95 % CI 1.04-8.26, p = 0.04), Helicobacter pylori infection (OR 2.80, 95 % CI 1.35-5.80, p < 0.01) and histologic intestinal-subtype (OR 2.14, 95 % CI 1.07-4.30, p = 0.03).

CONCLUSIONS:

tumor bleeding increases 90-days mortality in patients with uGC. Prevention of the first bleeding episode might improve outcome in these patients and the recognition of high-risk patients might help decision-making.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Helicobacter pylori / Infecciones por Helicobacter Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Rev Esp Enferm Dig Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Helicobacter pylori / Infecciones por Helicobacter Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Rev Esp Enferm Dig Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article